Stockscreener 앱 받기
432.47
1.94%
-8.017
전일 마감가:
$440.49
열려 있는:
$437.81
하루 거래량:
190.41K
Relative Volume:
0.17
시가총액:
$56.63B
수익:
$3.21B
순이익/손실:
$43.57M
주가수익비율:
1,798.22
EPS:
0.2405
순현금흐름:
$221.36M
1주 성능:
-5.28%
1개월 성능:
-6.01%
6개월 성능:
+56.19%
1년 성능:
+58.68%
1일 변동 폭
$430.83
$438.89
1주일 범위
$417.00
$457.26
52주 변동 폭
$205.87
$495.55
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
명칭
Alnylam Pharmaceuticals Inc
전화
(617) 551-8200
주소
675 WEST KENDALL STREET, CAMBRIDGE, MA
ALNY을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
432.00 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.77 | 105.61B | 11.74B | 3.68B | 3.50B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
645.06 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
843.11 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.22 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-08-04 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-08-04 | 업그레이드 | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | 재개 | Raymond James | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-03-31 | 개시 | Redburn Atlantic | Buy |
| 2025-03-24 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2024-11-12 | 다운그레이드 | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-08-16 | 업그레이드 | Goldman | Neutral → Buy |
| 2024-02-16 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2023-10-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-05-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | 개시 | SMBC Nikko | Neutral |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-01-18 | 개시 | Canaccord Genuity | Buy |
| 2022-09-09 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-06-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-06-07 | 개시 | William Blair | Outperform |
| 2022-04-25 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | 개시 | Citigroup | Buy |
| 2022-02-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-01-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | 업그레이드 | Goldman | Neutral → Buy |
| 2021-11-22 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-10-04 | 업그레이드 | UBS | Neutral → Buy |
| 2021-08-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-02-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-02-12 | 재확인 | H.C. Wainwright | Buy |
| 2021-01-25 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | 재개 | Berenberg | Hold |
| 2020-09-08 | 개시 | Citigroup | Buy |
| 2020-08-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-04-24 | 재개 | Evercore ISI | Outperform |
| 2020-03-19 | 개시 | Berenberg | Buy |
| 2019-12-19 | 재확인 | Chardan Capital Markets | Buy |
| 2019-11-20 | 개시 | Oppenheimer | Outperform |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Goldman | Neutral |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-03-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | 개시 | UBS | Neutral |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-13 | 재확인 | Stifel | Buy |
| 2018-08-07 | 업그레이드 | Stifel | Hold → Buy |
| 2018-05-04 | 재확인 | Stifel | Hold |
| 2018-03-28 | 개시 | Evercore ISI | In-line |
모두보기
Alnylam Pharmaceuticals Inc 주식(ALNY)의 최신 뉴스
Regression analysis insights on Alnylam Pharmaceuticals Inc. performanceNew Guidance & Safe Entry Point Alerts - newser.com
How Investors May Respond To Alnylam Pharmaceuticals (ALNY) Surging Revenue and Raised 2025 Guidance - simplywall.st
Will Alnylam Pharmaceuticals Inc. continue its uptrendPortfolio Return Report & AI Enhanced Execution Alerts - newser.com
Alnylam Pharmaceuticals Scores Relative Strength Rating Upgrade - Investor's Business Daily
Why global investors buy Alnylam Pharmaceuticals Inc. (DUL) stockMarket Volume Summary & Target Return Focused Stock Picks - newser.com
What data driven models say about Alnylam Pharmaceuticals Inc.’s future2025 Earnings Surprises & Community Consensus Trade Alerts - newser.com
Using data filters to optimize entry into Alnylam Pharmaceuticals Inc.July 2025 Momentum & Risk Managed Investment Entry Signals - newser.com
How to monitor Alnylam Pharmaceuticals Inc. with trend dashboardsBull Run & Safe Capital Growth Stock Tips - newser.com
Can Alnylam Pharmaceuticals Inc. (DUL) stock sustain institutional flows2025 Stock Rankings & Growth Oriented Trading Recommendations - newser.com
What RSI levels show for Alnylam Pharmaceuticals Inc. (DUL) stockJuly 2025 Intraday Action & Safe Entry Trade Reports - fcp.pa.gov.br
Has Alnylam Pharmaceuticals Inc. found a price floorWeekly Stock Analysis & AI Based Buy/Sell Signal Reports - newser.com
How risky is Alnylam Pharmaceuticals Inc. (DUL) stock compared to peersTrade Performance Summary & Verified High Yield Trade Plans - newser.com
Why Alnylam Pharmaceuticals Inc. stock is recommended by analystsWeekly Stock Summary & Free Weekly Chart Analysis and Trade Guides - newser.com
Can Alnylam Pharmaceuticals Inc. (DUL) stock sustain revenue momentumJuly 2025 Closing Moves & Momentum Based Trading Signals - newser.com
Will Alnylam Pharmaceuticals Inc. stock deliver shareholder valueRate Cut & Weekly Sector Rotation Insights - fcp.pa.gov.br
Is Alnylam Pharmaceuticals Inc. (DUL) stock vulnerable to rate hikesJuly 2025 Pullbacks & Daily Stock Trend Watchlist - newser.com
Is Alnylam Pharmaceuticals Inc. (DUL) stock overpriced at current multiplesWeekly Stock Summary & High Accuracy Investment Entry Signals - newser.com
Combining machine learning predictions for Alnylam Pharmaceuticals Inc.July 2025 Decliners & Short-Term Trading Opportunity Alerts - newser.com
How to recover losses in Alnylam Pharmaceuticals Inc. stock2025 Biggest Moves & Short-Term Trading Alerts - newser.com
Published on: 2025-11-05 21:04:23 - newser.com
What downside risks could hit Alnylam Pharmaceuticals Inc. (DUL) stockStock Surge & Stock Portfolio Risk Control - newser.com
Published on: 2025-11-05 12:16:44 - newser.com
Is Alnylam Pharmaceuticals Fairly Priced After FDA Approval Drives 81.3% Rally in 2025? - simplywall.st
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by Burney Co. - MarketBeat
Alnylam Pharma (ALNY) Receives a Rating Update from a Top Analyst - The Globe and Mail
Simon Quick Advisors LLC Acquires New Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Royalty Pharma Buys Royalty Interest in Alnylam Pharmaceuticals' Amvuttra From Blackstone Life Sciences for $310 Million - MarketScreener
Top 20 biopharma companies Q3 2025 market cap up 4% despite headwinds - Yahoo Finance
(ALNY) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Alnylam (NASDAQ: ALNY) to present Nov 10 & Nov 19 at UBS and Jefferies; live webcasts - Stock Titan
Alnylam to Webcast Presentations at Upcoming November Investor Conferences - Business Wire
Royalty Pharma Acquires $310 Million Royalty Interest in Alnylam's AMVUTTRA from Blackstone Life Sciences - Quiver Quantitative
Royalty Pharma (NASDAQ: RPRX) acquires 1% AMVUTTRA royalty for $310M from Blackstone - Stock Titan
Hussman Strategic Advisors Inc. Sells 2,100 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Is Alnylam Pharmaceuticals Inc. reversing from oversold territoryInflation Watch & Low Drawdown Investment Ideas - newser.com
Amalgamated Bank Boosts Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Assetmark Inc. Increases Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Is Alnylam Pharmaceuticals Inc. stock dividend yield sustainableJuly 2025 Review & Target Return Focused Picks - newser.com
New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline - GlobeNewswire Inc.
Alnylam Pharmaceuticals Inc (ALNY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Alnylam Pharmaceuticals Inc 주식 (ALNY) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Greenstreet Yvonne | Chief Executive Officer |
Oct 02 '25 |
Sale |
452.05 |
8,924 |
4,034,085 |
65,409 |
| Tanguler Tolga | EVP, Chief Commercial Officer |
Oct 02 '25 |
Sale |
452.05 |
1,405 |
635,126 |
27,438 |
| Fitzgerald Kevin Joseph | CSO & EVP, Head of Research |
Oct 02 '25 |
Sale |
452.05 |
2,441 |
1,103,451 |
25,231 |
| Garg Pushkal | EVP Chief R&D |
Oct 03 '25 |
Sale |
451.48 |
3,022 |
1,364,387 |
20,221 |
| Garg Pushkal | EVP Chief R&D |
Oct 02 '25 |
Sale |
452.05 |
2,937 |
1,327,675 |
23,243 |
0.47%
자본화:
|
볼륨(24시간):